ArticleAsia Pacific allergy2012
Management of chronic urticaria in Asia: 2010 AADV consensus guidelines.
Article in Asia Pacific allergy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 38 citations in OpenAlex.
- Trial
- Night-time sedating H1 -antihistamine increases daytime somnolence but not treatment efficacy in chronic spontaneous urticaria: a randomized controlled trial.The British journal of dermatology · 2014Trial
- A comprehensive clinical evaluation of levocetirizine in the treatment of chronic urticaria in children.Frontiers in pharmacology · 2025Article
- Monoclonal Antibodies in Treating Chronic Spontaneous Urticaria: New Drugs for an Old Disease.Journal of clinical medicine · 2022Review
- Insights into urticaria in pediatric and adult populations and its management with fexofenadine hydrochloride.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Review
- Risk Factors for Acute Urticaria in Central California.International journal of environmental research and public health · 2021Article
- The Efficacy of a Two-Fold Increase of H1-Antihistamine in the Treatment of Chronic Urticaria - the Vietnamese Experience.Open access Macedonian journal of medical sciences · 2019Article
- Diagnosis and treatment of urticaria in primary care.Northern clinics of Istanbul · 2019Review
- Chronic Urticaria: Comparisons of US, European, and Asian Guidelines.Current allergy and asthma reports · 2018Review
- A preliminary study on efficacy of rupatadine for the treatment of acute dengue infection.Scientific reports · 2018Article
- Selecting optimal second-generation antihistamines for allergic rhinitis and urticaria in Asia.Clinical and molecular allergy : CMA · 2017Article
- Role of bilastine in the management of allergic rhinitis and urticaria: an Asia-Pacific consensus statement.Asia Pacific allergy · 2016Review
- Chronic urticaria: Indian context-challenges and treatment options.Dermatology research and practice · 2013Review
- Chronic urticaria and use of statins.Asia Pacific allergy · 2012Article
- Asia Pacific Allergy: a successful first year and the future.Asia Pacific allergy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This guideline is a result of a consensus reached during the 19th Asian-Australasian Regional Conference of Dermatology by the Asian Academy of Dermatology and Venereology Study Group in collaboration with the League of Asian Dermatological Societies in 2010. Urticaria has a profound impact on the quality of life in Asia and the need for effective treatment is required. In line with the EAACI/GA(2)LEN/EDF/WAO guideline for the management of urticaria the recommended first-line treatment is new generation, non-sedating H1-antihistamines. If standard dosing is ineffective, increasing the dosage up to four-fold is recommended. For patients who do not respond to a four-fold increase in dosage of non-sedating H1-antihistamines, it is recommended that therapies such as H2-antihistamine, leukotriene antagonist, and cyclosporine A should be added to the antihistamine treatment. In the choice of second-line treatment, both their costs and risk/benefit profiles are the most important considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.